1. Introduction {#sec1}
===============

Sézary syndrome (SS) is a rare subset of primary cutaneous T-cell lymphoma (CTCL) with an aggressive clinical course \[[@B19], [@B56]\]. SS typically presents with generalised skin lesions or erythroderma, intense pruritus, and peripheral lymphadenopathy. A blood test will reveal atypical T-lymphocytes with convoluted nuclei, Sézary cells, which are often associated with a cutaneous T-cell lymphoma \[[@B56]--[@B55]\]. Recent studies have revealed complex genetic aberrations affecting almost all chromosomes \[[@B47]--[@B50]\] with loss of heterozygosity (LOH), \[[@B23], [@B38]--[@B51]\] and deregulation of several genes, \[[@B45]--[@B9]\] and epigenetic changes \[[@B41], [@B49]\] in SS. Despite this progress, the key molecular targets underlying the pathogenesis of this type of skin lymphoma remain elusive.

Single nucleotide polymorphism (SNP) denotes a single base in the DNA sequence that differs from the usual base at that position. Millions of SNPs have been catalogued in the human genome, which may be responsible for disease such as cancer (<http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp>). SNP microarray is a powerful genome research technique designed for the identification of SNP and dose change within the whole genome \[[@B8]--[@B31]\]. This method has been widely used to investigate SNP copy number change and LOH in cancer genome in a variety of medical and biological subjects \[[@B11]--[@B36]\]. However, there has been no report describing the use of SNP microarray to assess genomewide SNP copy number change and LOH in SS in the literature (<http://www.ncbi.nlm.nih.gov/sites/entrez>).

To address this issue we initially performed SNP microarray on DNA samples isolated from biopsies of skin lesions and peripheral blood mononuclear cells (PBMCs) of patients with SS by using Affymetrix GeneChip Mapping 10K Xba assay. Then we assessed gene-specific SNP copy number changes in same DNA samples with ABI TaqMan SNP genotyping assays to compare and verify the findings from Affymetrix 10K SNP microarray analysis. Finally, we conducted a literature review on LOH findings of patients with SS. Our findings are presented here in this paper.

2. Materials and Methods {#sec2}
========================

2.1. Sample Selection and DNA Preparation {#sec2.1}
-----------------------------------------

Eleven patients with Sézary syndrome were selected for this study according to the World Health Organization and the European Organization for Research and Treatment of Cancer diagnosis criteria for CTCL \[[@B56]\]. Genomewide SNP analysis was performed on 8 of these SS cases using Affymetrix SNP microarray. Five of these 8 SS cases plus additional 3 cases were further assessed with SNP quantitative real-time PCR in this study. Briefly, a total of 16 DNA samples (13 samples for SNP microarray and 3 additional samples for SNP qPCR), which were taken prior to treatment, were extracted from both PBMCs and biopsied skin lesions from these SS cases (Figures [1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). This was conducted by using QIAGEN Genomic-tip 100/G kit (QIAGEN Ltd, West Sussex, UK) according to the manufacturer\'s instruction (<http://www1.qiagen.com/>). DNA concentrations and purity were determined with the NanoDrop ND-1000 spectrophotometer (NanoDrop, Rockland, Del, USA). Local ethical approval for the sampling procedures was obtained previously \[[@B23]--[@B25], [@B20]\] and the use of the stored DNA samples for this study was approved by the Research Ethical Committee at Barts and Royal London School of Medicine and Dentistry, Queen Mary University of London.

2.2. Single Nucleotide Polymorphism Microarray Assay {#sec2.2}
----------------------------------------------------

Affymetrix SNP microarray analysis of 13 DNA samples including 5 paired PBMCs and skin biopsies from 8 SS patients ([Figure 1](#fig1){ref-type="fig"}) was conducted according to the standard GeneChip Mapping 10 K (V2.0) Xba Assay protocol (Affymetrix Inc., Santa Clara, Calif, USA). Briefly, 350 ng of DNA was digested with XbaI and ligation to the XbaI adaptor prior to PCR amplification (35 cycles) using AmpliTaq Gold with Buffer II (Applied Biosystems, Foster City, Calif, USA). Hybridised arrays were processed with an Affymetrix Fluidics Station 450 and fluorescence signals were detected using the Affymetrix GeneChip Scanner 3000. Signal intensity data was assessed with the GeneChip DNA analysis software (<http://www.affymetrix.com/products/arrays/specific/10k.affx>) based on a model algorithm to generate SNP calls \[[@B15]\] and subsequent bioinformative analysis was carried out using an in-house software called GOLF (<http://www.bioinformatics.cancerresearchuk.org/cazier01>) developed by Professor Young \[[@B7]\] and a publicly accessible software named IdeogramBrowser Software (<http://www.informatik.uni-ulm.de/ni/staff/HKestler/ideo/doc.html>).

2.3. SNP Quantitative Real-Time PCR Assay {#sec2.3}
-----------------------------------------

To verify the results of Affymetrix SNP microarray analysis of SS cases in this study, SNP qPCR assay was performed to test 10 DNA samples from 8 SS patients including 7 samples from 5 SS cases used in above SNP microarray and 3 samples from additional 3 SS cases ([Figure 3](#fig3){ref-type="fig"}). This experiment was carried out by means of an ABI Prism 7900 sequence detection system using the TaqMan PCR Master Mix with TaqMan SNP genotyping assays (<http://www3.appliedbiosystems.com/applicationstechnolo-gies/real-timepcr/index.htm>). These assays amplify 12 genes within the chromosomal regions showing frequent SNP copy number changes identified in this study ([Figure 2](#fig2){ref-type="fig"}). Additional 2 SNP genotyping assays amplifying beta-2-microglobulin (B2M, rs935885, C_12080829_10) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, rs3741918, C_27510362_10) were used as the internal quality controls. qPCR reactions contained 900 nmol primers, 200 nmol probes, 400 mM each dATP, dCTP and dGTP, 800 mM dUTP, 1 U Amplitaq Gold DNA polymerase, 0.2 U AmpErase uracil N-glycosylase (UNG), and 13 TaqMan buffer in a total volume of 25 *μ*L in 96-well microtiter plate (Applied Biosystems). After a decontamination step at 50°C, a two-step protocol was followed for 50 cycles: 95°C for 15 s and 61°C for 1 min. SNP qPCR data analysis was conducted as previously described \[[@B43]\] with ABI SNPbrowser Software (<http://marketing.appliedbiosystems.com/mk/get/snpb_landing>).

2.4. SNP Loss of Heterozygosity Expression Profiling {#sec2.4}
----------------------------------------------------

We have previously put forward a concept of functional copy number changes in cancer cells \[[@B29]\]. To further test our hypothesis in this study, we assume a SNP LOH gene cluster in SS is bioinformatically significant or functional if it is capable of separating all SS cases from normal control (NC) samples. This test was carried out through a data mining experiment by using a bioinformative method developed by us \[[@B29]\]. In this experiment, the effect of SNP LOH detected in this study on gene expression profiling in SS cases conducted in previous studies \[[@B26], [@B30], [@B28]\] was tested as before \[[@B29]\]. The procedures were briefly described as follows. We initially created gene lists from 9 chromosomal regions showing frequent LOH (\>3 per region) at SNP level seen in SS ([Table 1](#tab1){ref-type="table"}) by using IdeogramBrowser Software and UCSC Human Gene Sorter (<http://www.genome.ucsc.edu/>). Then we imported these 9 gene-lists into GeneSpring software version 7 (<http://www.sigenetics.com/>), which contained a genome/raw data of gene expression profile from 6 SS patients who were treated with photopheresis therapy and 2 healthy individuals generated by using Affymetrix GeneChip U133A (<http://www.affymetrix.com/products/arrays/specific/hgu133av2.affx>). Of 6 SS cases analysed with Affymetrix gene expression microarray the 3 cases were also tested by above Affymetrix SNP microarray. Finally, we analysed the selected 9 gene lists by using the clustering tool of GeneSpring to generate gene tree and condition tree, a supervised clustering, which enables direct visualisation of sample congregation and separation \[[@B29]\].

2.5. Comparison with Published Data on LOH at Microsatellite Loci in SS {#sec2.5}
-----------------------------------------------------------------------

The genomic region where SNPs span on Affymetrix 10K GeneChip used in this study is equivalent to that covered by 400 microsatellite (MS) loci (<http://www.affymetrix.com/products/arrays/specific/10k.affx>). There have been several publications describing LOH at MS loci on limited chromosomes in CTCL including SS \[[@B23], [@B38]--[@B51], [@B10]\]. To compare previous findings with this study, we reanalysed previous published data on MS LOH at chromosomes 1 and 10q through fine mapping of each MS locus, which was linked to individual gene and SNP by using NCBI ENTREZ GENE and ENTREZ SNP database (<http://www.ncbi.nlm.nih.gov/>).

3. Results {#sec3}
==========

3.1. SNP Microarray {#sec3.1}
-------------------

In this study, paired DNA samples from PBMCs and skin lesions from 5 of 8 SS cases were analysed with Affymetrix 10 K SNP microarray, which showed similar SNP homozygous changes between the paired samples indicating they are coming from the same individual. There was a difference in SNP fingerprint among 8 different SS cases signifying the absence of sample contamination. As [Figure 1](#fig1){ref-type="fig"} shows, frequent homozygous changes (\>3 per chromosome) including gain, loss, and uniparental disomy (UPD) were seen to distribute throughout almost an entire genome except of chromosomes 14, 19 and 22.

As [Figure 2](#fig2){ref-type="fig"} shows there were frequent SNP copy number changes (\>3 per chromosome) at chromosomes 1, 2p, 3, 4q, 5q, 6, 7p, 8, 9, 10, 11, 12q, 13, 14, 16q, 17, and 20, which are not only consistent with above homozygous changes but also in line with previous CGH findings in SS \[[@B24]\].

In this study, a weak and/or smear band of TCR gene was detected in skin DNA samples, while a strong monoclonal TCR gene band was seen in PBMC DNA samples (data not shown), suggesting that only a few tumour cells were present in skin samples and sample contamination was negligible. Overall, a frequent LOH was noted in 5 paired SS cases at 9 chromosomal regions including 1p36p33, 2q21q24, 8q22q24, 9q31q34, 10p11q26, 11q21q25, 13q11q12, 16q21q23, and 17p13q11 ([Table 1](#tab1){ref-type="table"}), which are to some extent similar to previous reports on LOH at certain chromosome regions \[[@B23], [@B38]--[@B51]\].

3.2. SNP qPCR Assay {#sec3.2}
-------------------

To further confirm SNP microarray findings, SNP qPCR was utilised to test DNA samples from 5 of 8 SS cases (case number 1, 3, 5, 6 and 8) analysed with Affymetrix 10K SNP microarray using ABI TaqMan SNP genotyping assay (63%) and 3 additional cases. As [Figure 3](#fig3){ref-type="fig"} shows, frequent SNP copy number loss (\>2 cases) at the FAT gene (rs1280100) at 4q35 was observed in 6 of 8 SS cases (number 1, 3, 6, 8, 9, and 10) (75%), followed by VEGFC (rs1485765) at 4q34.1q34.3 (cases  3, 6, 8, and 9) (50%), NFIB (rs2382446) at chromosome 12 (cases  5, 6 and 8) (38%), and TRIM16 (rs9909923) at 17p11.2 (cases  3, 6, and 8) (38%). While frequent SNP copy number gain (\>2 cases) was also noted at the AKR1C3 gene (rs7068685, 50%), VEGFC (rs1485765, 38%), and TAGLN (rs2269397, 38%).

SNP copy number changes were most frequent present in SS case  3, which showed losses of genes of RAB1A (rs10519011, 2p14), VEGFC, **FAT**, AKR1C3, TRIM16, and PLS3 (rs5987755, Xq23) as well as gains of genes of TAGLN (rs2269397, 11q23.2) and NFIB. This was followed by case  5, which had gains of RAB1A, STAT4 (rs13001658, 2q32.2q32.3), VEGFC, TWIST1 (rs2106892, 7p21.2), TAGLN, and PLS3, and loss of NFIB. Case  6 revealed losses of VEGFC, **FAT**, NFIB and TRIM16, and gain of AKR1C3; case  8 demonstrated losses of VEGFC, **FAT**, AKR1C3, NFIB, and TRIM16 ([Figure 3](#fig3){ref-type="fig"}). Overall these SNP copy number changes, detected by using qPCR with ABI TaqMan SNP genotyping assay, were consistent with those identified by using Affymetrix 10K SNP microarray as shown in [Figure 2](#fig2){ref-type="fig"}.

3.3. SNP LOH Expression Profiling {#sec3.3}
---------------------------------

The impact of SNP LOH gene cluster on gene expression pattern was further tested in this study. As shown in [Figure 4](#fig4){ref-type="fig"}, the clusters of 2 NCs appeared at the right end of the heatmap and the clusters of 6 SS cases were present in the middle and at the left end of the heatmap. This clearly showed that two groups were separated and different. Over the 9 SNP LOH gene lists analysed in this study, 3 (33%) showed gene expression patterns of the separation of 6 SS cases from 2 NCs ([Table 1](#tab1){ref-type="table"}). This included SNP LOH gene clusters at 9q31q34 (40 genes), 10p11q26 (111 genes), and 13q11q12 (15 genes) ([Figure 4](#fig4){ref-type="fig"}). Each individual gene in these 3 gene clusters is listed in [Table 2](#tab2){ref-type="table"}. However, the remaining 6 SNP LOH gene lists revealed a mixed gene expression pattern without the separation of SS from NCs ([Table 1](#tab1){ref-type="table"}).

3.4. Refining Previous SS LOH Data and Comparing with This Study {#sec3.4}
----------------------------------------------------------------

Previous studies have shown LOH on several chromosomes including chromosomes 1 and 10q \[[@B23], [@B38]--[@B51], [@B10]\]. The 10K SNP microarray gene chip used in this study is equivalent to the genetic distance covered by 400 MS. This allows us to compare SNP LOH identified in this study with MS LOH described in those previous studies. Frequent LOH at MS loci D1S247 (rs11372930) at 1p36 and D10S562 (rs4128597) at 10q25.3 ([Figure 5](#fig5){ref-type="fig"}) reported in previous studies \[[@B23], [@B20], [@B51]\] were seen in this study.

4. Discussion {#sec4}
=============

This integrated genomic study has for the first time revealed genomewide SNP copy number change and LOH as well as SNP LOH gene expression profiling in SS cases. Although the number of SS cases tested in this study was small, the patterns of SNP copy number change and LOH identified in SS cases are generally in line with previous metaphase-/array-CGH \[[@B47]--[@B50]\] and MS LOH studies \[[@B23], [@B38], [@B40]--[@B51], [@B10]\], suggesting the high efficiency and reliability of the methods used. In addition some novel findings emerged. This includes the presence of SNP copy number loss at the FAT gene (4q35) in most SS cases and the separation of all SS cases from NC samples by SNP LOH gene clusters at chromosome regions of 9q31q34, 10p11q26, and 13q11q12. Although all of these results will need to be validated in larger cohorts of samples from SS patients in the future, they do provide some intriguing information for our current understanding of the molecular pathogenesis of this type of lymphoma and suggest the possibility of presence of functional SNP LOH in SS tumour cells at least from the point of view of bioinformatics.

Sézary syndrome is a rare form of CTCL with an aggressive clinical course and it also likely represents the leukaemic phase of mycosis fungoides \[[@B19], [@B56]\]. Like any other advanced stage of malignancies, SS accumulates a variety of genetic and epigenetic events including alterations of tumour suppressor genes, oncogenes, and some key house-keeping genes \[[@B20], [@B41], [@B49], [@B34]\]. Previous studies on SS have shown complex genetic aberrations affecting almost all chromosomes with copy number losses being the dominant abnormalities, which mainly involve chromosomes 1p, 6q, 9, 10, 13q, and 17p \[[@B47]--[@B50]\] and the presence of LOH at MS loci on chromosomes 1p, 9p, 10q, and 17p in tumour cells \[[@B23], [@B38]--[@B51], [@B10]\]. In addition, downregulation of several genes including MXI1 (10q24q25) and upregulation of genes such as TWIST1 (7p21.2) and PLS3 (Xq23) have also been described in this malignancy \[[@B45]--[@B9]\]. Similar results were obtained in this study, which showed SNP copy number change on chromosomes 1, 2p, 3, 4q, 5q, 6, 7p, 8, 9, 10, 11, 12q, 13, 14, 16q, 17, and 20, and LOH at 1p, 2q, 8q, 9q, 10, 11q, 13q, 16q, and 17 as well as SNP copy number gains of TWIST1 and PLS3 in 2 SS cases, further indicating the high efficiency and reliability of the integrated genomic experiments conducted in this study.

Although there are different definitions for loss of heterozygosity in literature, LOH is generally defined as a locus or loci at which a deletion or other process has converted the locus from heterozygosity to homozygosity or hemizygosity. In terms of cancer, LOH signifies that in tumour cells carrying a mutated allele of a tumour suppressor gene, the gene becomes fully inactivated when the cell loses a large part of the chromosome carrying the wild-type allele (<http://www.ncbi.nlm.nih.gov/cancerchromosomes>). LOH is traditionally used as a molecular tool to identify a tumour-suppressor gene but it also represents one of the most common molecular features of cancer cells \[[@B28], [@B21]--[@B27]\]. Previous studies have shown LOH at MS loci on chromosomes 1p, 9p, 10q, 12q, 13q, 17p, and 19 in CTCL including SS \[[@B23], [@B38]--[@B51], [@B10]\]. This was supported by previous conventional cytogenetics and metaphase and array-based CGH studies, which revealed DNA copy number losses at these chromosomal regions \[[@B47]--[@B50], [@B10]\]. In this study LOH at SNP level on 9 chromosomal regions (1p, 2q, 8q, 9q, 10, 11q, 13q, 16q, and 17) was identified in SS cases by using Affymetrix 10 K GeneChip, which covers approximately 400 MS loci. There was an overlap between this and previous studies on LOH at chromosome 1p (D1S247) and 10q (D10S562). Previous studies also suggested LOH at 1p and 10q associated with late stage CTCL \[[@B38]--[@B40], [@B51], [@B10]\]. In addition, copy number losses were described in these 9 chromosomal regions by using molecular cytogenetic techniques as discussed above. Furthermore, these findings were subsequently validated by extensive SNP qPCR test in this study. Taking together all of these results suggest that some of these SNP LOH and copy number changes are likely to be associated with the pathogenesis of SS.

The FAT gene, which is expressed at high levels in a number of foetal epithelia, is an ortholog of the Drosophila fat gene. FAT encodes a tumour suppressor essential for controlling cell proliferation during Drosophila development. Its product is a member of the cadherin superfamily, a group of integral membrane proteins characterised by the presence of 34 tandem cadherin-type repeats as well as five epidermal growth factor-like repeats and one laminin A-G domain with possible functions as an adhesion molecule and/or signalling receptor, which are likely to be associated with developmental processes and cell communication (<http://www.ncbi.nlm.nih.gov/gene/2195>). The FAT gene is located on human chromosome 4q35. Previous molecular cytogenetic studies have revealed copy number losses at this chromosomal region in a variety of cancers (<http://www.progenetix.org/cgi-bin/pgCasesMatrixPlotter.cgi>). Furthermore deletion/LOH and absent expression of FAT have also been found in oral cancer \[[@B33]\] and human astrocytic tumours \[[@B3]\]. Intriguingly, in this study SNP copy number loss of FAT was observed in three-quarter of SS cases and reduced gene expression of FAT was also noted in most cutaneous squamous cell carcinoma cases (data not shown) no spare SS RNA samples are available for qPCR testing. These results further indicate the tumour suppressor role of FAT and also suggest that loss of FAT is relevant to SS pathology.

Interindividual copy number variation/polymorphism (CNV/P) is thought to be the manifestation of a considerable and unanticipated plasticity of the human genome. CNV/P constitutes a major source of interindividual genetic variation that could explain variable penetrance of inherited diseases and variation in the phenotypic expression of aneuploidies and sporadic traits \[[@B2], [@B32]\]. There is increasing evidence showing de novo CNV/P as a major cause of mental retardation and several other complex disorders \[[@B16]--[@B18], [@B15], [@B37]\]. Cytogenetically CNV/P or copy number changes (CNCs) have long been described in cancer cells (<http://www.cgap.nci.nih.gov/Chromosomes/Mitelman>, <http://www.progenetix.net/>). As discussed above SS has been found with frequent CNCs at several chromosomal regions \[[@B47]--[@B1]\]. Some of these CNCs may have a net effect on gene expression as previous expression profiling studies on SS have revealed up- and downregulations of several genes, which are mapped within the chromosomal regions harbouring these CNCs \[[@B45]--[@B9]\]. From, bioinformatic point of view these CNCs may be functional. Whilst the remaining CNCs (CNV/P) may not have any net effect at all and are therefore nonfunctional. To test this hypothesis we developed a simple bioinformatics strategy through the analysis of the expression profiling of CNCs gene clusters commonly presented in SS to see if SS cases can be separated from NCs. We found separated expression patterns in 4 of 17 CNCs gene clusters \[[@B29]\]. In this study, we expanded the scope of our bioinformatics experiment by examining the impact of common SNP LOH gene clusters identified in SS cases with Affymetrix 10 K SNP microarray on gene expression patterns in SS cases detected using gene expression microarray with Affymetrix GeneChip U133A and dedicated software. There was a separation of all 6 SS cases from 2 NCs by 3 of 9 SNP LOH gene clusters. This includes 9q31q34, 10p11q26, and 13q11q12, which lie within the chromosomal regions showing frequent LOH and/or DNA copy number loss in SS. In addition, decreased expression of MXI1 in SNP LOH gene cluster at 10p11q26 has been described in SS previously \[[@B14]\]. All of these findings suggest that the 3 SNP LOH gene clusters may be functional in terms of bioinformatics and relevant to SS pathology. There are also a number of genes in these 3 SNP LOH gene lists which have not been described in SS before. Further functional studies, including proteomic analysis, are therefore necessary to elucidate the oncogenic role of these genes in the initiation and progression of SS and other types of CTCL.
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![Illustration of a diagram of genomewide SNP homozygosity mapping in 8 SS cases (No. 1--8) detected with Affymetrix GeneChip Human Mapping 10K Array (<http://www.affymetrix.com/products/arrays/specific/10k.affx>) and analysed by using GOLF software (<https://bioinformatics.cancerresearchuk.org/cazier01>). Here each red-coloured line represents copy number gain of individual SNP, green-coloured line and block stand for SNP copy number loss, black-coloured line and block denote balanced/neutral SNP copy number or uniparental disomy. Similar SNP homozygosity profile is present in paired DNA samples from the biopsied skin lesion (S) and peripheral blood (B) isolated from individual patient with SS on the right end of the diagram. Frequent SNP homozygous changes (\>3) are seen on almost all autosomes consistent with SNP copy number alterations shown in [Figure 2](#fig2){ref-type="fig"}. The remarkable changes on X chromosome were used as the internal quality control for the 10K SNP array experiment as green represents X chromosome copy number loss or monosomy indicating male sex, and black signifies balanced or disomy X chromosome denoting female.](GRI2011-980150.001){#fig1}

![Illustration of an ideogram of genomewide SNP copy number changes in 8 SS cases identified by using Affymetrix GeneChip Human Mapping 10K Array as above and analysed with the IdeogramBrowser Software (<http://www.informatik.uni-ulm.de/ni/staff/HKestler/ideo/doc.html>). Here each red-coloured dot represents copy number loss of individual SNP and green-coloured dot stands for SNP copy number gain. Frequent SNP copy number changes at chromosomes 1, 2p, 3, 4q, 5q, 6, 7p, 8, 9, 10, 11, 12q, 13, 14, 16q, 17, and 20 are clearly visible.](GRI2011-980150.002){#fig2}

![A summary of SNP copy number changes of 12 genes in 10 SS samples by using qPCR with ABI TaqMan SNP genotyping assay to verify the results of Affymetrix 10K SNP microarray analysis of SS in this study. Here red-coloured rectangular bar denotes SNP copy number loss against internal controls of B2M and GAPDH, green-coloured bar stands for SNP copy number gain, yellow-coloured bar represents balanced/neutral or normal SNP copy number, and gray-coloured bar indicates noninformative. Frequent SNP copy number losses of VEGFC, FAT, NFIB, and TRIM16 are clearly visible.](GRI2011-980150.003){#fig3}

![Illustration of a heatmap of gene expression profile of SNP LOH at 13q11q12 gene cluster (15 genes). Here each column represents one test sample and each coloured rectangular bar signifies each individual gene. The colouration of each bar indicates the expression level of individual gene, which has been reported previously \[[@B26], [@B30], [@B28]\] and is not the focus of this study. The separation of 6 Sézary syndrome cases (SS, left and middle) from 2 normal controls (NC, right) is clearly visible and two test groups are different.](GRI2011-980150.004){#fig4}

![A summary of reanalysis of previously published LOH at 18 microsatellite loci on 10q21q26 in SS and MF \[[@B51]\] with this study, in which each microsatellite locus is finely mapped and linked to individual gene and SNP via NCBI ENTREZ GENE and ENTREZ SNP database (<http://www.ncbi.nlm.nih.gov/>). Here black bar represents LOH, gray bar stands for noninformative, and white bar indicates microsatellite marker that is not available. One SNP within microsatellite locus D10S562 (bold) is also present in the SNP LOH cluster at 10p11q26 in this study ([Table 1](#tab1){ref-type="table"}).](GRI2011-980150.005){#fig5}

###### 

A summary of gene expression profile of LOH gene clusters.

  Chromosomal regions with LOH detected in this study   Number of genes   Separation of SS from NC\*
  ----------------------------------------------------- ----------------- ----------------------------
  1p36p33                                               80                N
  2q21q24                                               9                 N
  8q22q24                                               15                N
  9q31q34                                               40                P
  10p11q26                                              111               P
  11q21q25                                              205               N
  13q11q12                                              15                P
  16q21q23                                              74                N
  17p13q11                                              198               N

\*N: no separation between SS and NC, P: presence of separation between SS and NC.

###### 

A detailed gene list of the 3 LOH gene clusters separating SS from NC

  LOH gene clusters   Gene name      Common      Description
  ------------------- -------------- ----------- -----------------------------------------------------------------------------------------------------------
  9q31q34             221294_at      GPR21       G-protein-coupled receptor 21
                      221085_at      TNFSF15     Tumor necrosis factor (ligand) superfamily, member 15
                      220935_s\_at   CDK5RAP2    CDK5 regulatory subunit associated protein 2
                      220300_at      RGS3        Regulator of G-protein signalling 3
                      220202_s\_at   MNAB        Membrane-associated nucleic acid binding protein
                      220201_at      MNAB        Membrane-associated nucleic acid binding protein
                      219884_at      LHX6        LIM homeobox protein 6
                      218941_at      FBXW2       F-box and WD-40 domain protein 2
                      218489_s\_at   ALAD        Aminolevulinate, delta-, dehydratase
                      218487_at      ALAD        Aminolevulinate, delta-, dehydratase
                      218160_at      NDUFA8      NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8, 19 kDa
                      215813_s\_at   PTGS1       Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase)
                      214465_at      ORM2        Orosomucoid 2
                      214425_at      AMBP        Alpha-1-microglobulin/bikunin precursor
                      214040_s\_at   GSN         Gelsolin (amyloidosis, Finnish type)
                      211503_s\_at   RAB14       RAB14, member RAS oncogene family
                      210825_s\_at   STOM        Stomatin
                      210824_at      STOM        Stomatin
                      209162_s\_at   PRPF4       PRP4 pre-mRNA processing factor 4 homolog (yeast)
                      209161_at      PRPF4       PRP4 pre-mRNA processing factor 4 homolog (yeast)
                      208828_at      POLE3       Polymerase (DNA directed), epsilon 3 (p17 subunit)
                      208737_at      ATP6V1G1    ATPase, H+ transporting, lysosomal 13 kDa, V1 subunit G isoform 1
                      205599_at      TRAF1       TNF receptor-associated factor 1
                      205500_at      C5          Complement component 5
                      205477_s\_at   AMBP        Alpha-1-microglobulin/bikunin precursor
                      205128_x\_at   PTGS1       Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase)
                      205127_at      PTGS1       Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase)
                      205041_s\_at   ORM1        Orosomucoid 1
                      205040_at      ORM1        Orosomucoid 1
                      204449_at      PDCL        Phosducin-like
                      204448_s\_at   PDCL        Phosducin-like
                      203971_at      SLC31A1     Solute carrier family 31 (copper transporters), member 1
                      203823_at      RGS3        Regulator of G-protein signalling 3
                      203447_at      PSMD5       Proteasome (prosome, macropain) 26S subunit, non-ATPase, 5
                      201062_at      STOM        Stomatin
                      201061_s\_at   STOM        Stomatin
                      201060_x\_at   STOM        Stomatin
                      200928_s\_at   RAB14       RAB14, member RAS oncogene family
                      200927_s\_at   RAB14       RAB14, member RAS oncogene family
                      200696_s\_at   GSN         Gelsolin (amyloidosis, Finnish type)
                                                 
  10p11.21q26.3       32094_at       CHST3       Carbohydrate (chondroitin 6) sulfotransferase 3
                      222072_at      ADD3        Homo sapiens clone DT1P1A11 mRNA, CAG repeat region
                      221136_at      GDF2        Growth differentiation factor 2
                      219963_at      DUSP13      Dual specificity phosphatase 13
                      219957_at      RUFY2       RUN and FYVE domain containing 2
                      219543_at      MAWBP       MAWD binding protein
                      219509_at      MYOZ1       Myozenin 1
                      218878_s\_at   SIRT1       Sirtuin (silent mating type information regulation 2 homolog) 1 (*S. cerevisiae*)
                      218871_x\_at   GALNACT-2   Chondroitin sulfate GalNAcT-2
                      218445_at      H2AFY2      H2A histone family, member Y2
                      218249_at      ZDHHC6      Zinc finger, DHHC domain containing 6
                      218046_s\_at   MRPS16      Mitochondrial ribosomal protein S16
                      218006_s\_at   ZNF22       Zinc finger protein 22 (KOX 15)
                      218005_at      ZNF22       Zinc finger protein 22 (KOX 15)
                      216903_s\_at   CBARA1      Calcium binding atopy-related autoantigen 1
                      216345_at      KIAA0913    KIAA0913 protein
                      216037_x\_at   TCF7L2      Transcription factor 7-like 2 (T-cell specific, HMG-box)
                      216035_x\_at   TCF7L2      Transcription factor 7-like 2 (T-cell specific, HMG-box)
                      214878_at      ZNF37A      Zinc finger protein 37a (KOX 21)
                      214617_at      PRF1        Perforin 1 (pore forming protein)
                      214508_x\_at   CREM        cAMP responsive element modulator
                      214366_s\_at   ALOX5       Arachidonate 5-lipoxygenase
                      214348_at      TACR2       Tachykinin receptor 2
                      214338_at      DNAJB12     DnaJ (Hsp40) homolog, subfamily B, member 12
                      214322_at      CAMK2G      Calcium/calmodulin-dependent protein kinase (CaM kinase) II gamma
                      214136_at      NUDT13      Nudix (nucleoside diphosphate linked moiety X)-type motif 13
                      213952_s\_at   ALOX5       Arachidonate 5-lipoxygenase
                      213647_at      DNA2L       DNA2 DNA replication helicase 2-like (yeast)
                      212894_at      SUPV3L1     Suppressor of var1, 3-like 1 (*S. cerevisiae*)
                      212762_s\_at   TCF7L2      Transcription factor 7-like 2 (T-cell specific, HMG-box)
                      212761_at      TCF7L2      Transcription factor 7-like 2 (T-cell specific, HMG-box)
                      212759_s\_at   TCF7L2      Transcription factor 7-like 2 (T-cell specific, HMG-box)
                      212757_s\_at   CAMK2G      Calcium/calmodulin-dependent protein kinase (CaM kinase) II gamma
                      212669_at      CAMK2G      Calcium/calmodulin-dependent protein kinase (CaM kinase) II gamma
                      212594_at      PDCD4       Programmed cell death 4 (neoplastic transformation inhibitor)
                      212593_s\_at   PDCD4       Programmed cell death 4 (neoplastic transformation inhibitor)
                      212359_s\_at   KIAA0913    KIAA0913 protein
                      212322_at      SGPL1       Sphingosine-1-phosphate lyase 1
                      212321_at      SGPL1       Sphingosine-1-phosphate lyase 1
                      211809_x\_at   COL13A1     Collagen, type XIII, alpha 1
                      211668_s\_at   PLAU        plasminogen activator, urokinase
                      211343_s\_at   COL13A1     Collagen, type XIII, alpha 1
                      210956_at      PPYR1       Pancreatic polypeptide receptor 1
                      210671_x\_at   MAPK8       Mitogen-activated protein kinase 8
                      210588_x\_at   HNRPH3      Heterogeneous nuclear ribonucleoprotein H3 (2H9)
                      210477_x\_at   MAPK8       Mitogen-activated protein kinase 8
                      210318_at      RBP3        Retinol binding protein 3, interstitial
                      210171_s\_at   CREM        cAMP responsive element modulator
                      210110_x\_at   HNRPH3      Heterogeneous nuclear ribonucleoprotein H3 (2H9)
                      209910_at      SLC25A16    Solute carrier family 25 (mitochondrial carrier; Graves disease autoantigen), member 16
                      209869_at      ADRA2A      Adrenergic, alpha-2A-, receptor
                      209860_s\_at   ANXA7       Annexin A7
                      209834_at      CHST3       Carbohydrate (chondroitin 6) sulfotransferase 3
                      209817_at      PPP3CB      Protein phosphatase 3 (formerly 2B), catalytic subunit, beta isoform (calcineurin A beta)
                      209538_at      ZNF32       Zinc finger protein 32 (KOX 30)
                      209457_at      DUSP5       Dual specificity phosphatase 5
                      209045_at      XPNPEP1     X-prolyl aminopeptidase (aminopeptidase P) 1, soluble
                      208990_s\_at   HNRPH3      Heterogeneous nuclear ribonucleoprotein H3 (2H9)
                      208770_s\_at   EIF4EBP2    Eukaryotic translation initiation factor 4E binding protein 2
                      208769_at      EIF4EBP2    Eukaryotic translation initiation factor 4E binding protein 2
                      208535_x\_at   COL13A1     Collagen, type XIII, alpha 1
                      208453_s\_at   XPNPEP1     X-prolyl aminopeptidase (aminopeptidase P) 1, soluble
                      208381_s\_at   SGPL1       Sphingosine-1-phosphate lyase 1
                      208252_s\_at   CHST3       Carbohydrate (chondroitin 6) sulfotransferase 3
                      208152_s\_at   DDX21       DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 21
                      208095_s\_at   CAMK2G      Calcium/calmodulin-dependent protein kinase (CaM kinase) II gamma
                      207965_at      NEUROG3     Neurogenin 3
                      207630_s\_at   CREM        cAMP responsive element modulator
                      207543_s\_at   P4HA1       Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide I
                      207347_at      ERCC6       Excision repair cross-complementing rodent repair deficiency, complementation group 6
                      207127_s\_at   HNRPH3      Heterogeneous nuclear ribonucleoprotein H3 (2H9)
                      206747_at      KIAA0514    KIAA0514 gene product
                      206261_at      ZNF239      Zinc finger protein 239
                      206159_at      GDF10       Growth differentiation factor 10
                      206010_at      HABP2       Hyaluronan binding protein 2
                      205882_x\_at   ADD3        Adducin 3 (gamma)
                      205879_x\_at   RET         Ret proto-oncogene (multiple endocrine neoplasia and medullary thyroid carcinoma 1, Hirschsprung disease)
                      205479_s\_at   PLAU        Plasminogen activator, urokinase
                      204446_s\_at   ALOX5       Arachidonate 5-lipoxygenase
                      204445_s\_at   ALOX5       Arachidonate 5-lipoxygenase
                      204120_s\_at   ADK         Adenosine kinase
                      204119_s\_at   ADK         Adenosine kinase
                      203916_at      NDST2       N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 2
                      203666_at      CXCL12      Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1)
                      203187_at      DOCK1       Dedicator of cyto-kinesis 1
                      203079_s\_at   CUL2        Cullin 2
                      203078_at      CUL2        Cullin 2
                      203074_at      ANXA8       Annexin A8
                      202867_s\_at   DNAJB12     DnaJ (Hsp40) homolog, subfamily B, member 12
                      202866_at      DNAJB12     DnaJ (Hsp40) homolog, subfamily B, member 12
                      202865_at      DNAJB12     DnaJ (Hsp40) homolog, subfamily B, member 12
                      202777_at      SHOC2       soc-2 suppressor of clear homolog (C. elegans)
                      202731_at      PDCD4       Programmed cell death 4 (neoplastic transformation inhibitor)
                      202730_s\_at   PDCD4       Programmed cell death 4 (neoplastic transformation inhibitor)
                      202524_s\_at   SPOCK2      Sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 2
                      202523_s\_at   SPOCK2      Sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 2
                      202432_at      PPP3CB      Protein phosphatase 3 (formerly 2B), catalytic subunit, beta isoform (calcineurin A beta)
                      202364_at      MXI1        MAX interacting protein 1
                      202361_at      SEC24C      SEC24 related gene family, member C (*S. cerevisiae*)
                      201859_at      PRG1        Proteoglycan 1, secretory granule
                      201858_s\_at   PRG1        Proteoglycan 1, secretory granule
                      201753_s\_at   ADD3        Adducin 3 (gamma)
                      201752_s\_at   ADD3        Adducin 3 (gamma)
                      201376_s\_at   HNRPF       Heterogeneous nuclear ribonucleoprotein F
                      201366_at      ANXA7       Annexin A7
                      201034_at      ADD3        Adducin 3 (gamma)
                      200931_s\_at   VCL         Vinculin
                      200930_s\_at   VCL         Vinculin
                      200871_s\_at   PSAP        Prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy)
                      200866_s\_at   PSAP        Prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy)
                      200697_at      HK1         Hexokinase 1
                                                 
  13q11q12            36830_at       MIPEP       Mitochondrial intermediate peptidase
                      221995_s\_at   MRP63       Mitochondrial ribosomal protein 63
                      221771_s\_at   HSMPP8      M-phase phosphoprotein, mpp8
                      220753_s\_at   CRYL1       Crystallin, lambda 1
                      218479_s\_at   XPO4        Exportin 4
                      213262_at      SACS        Spastic ataxia of Charlevoix-Saguenay (sacsin)
                      208742_s\_at   SAP18       sin3-associated polypeptide, 18 kDa
                      208741_at      SAP18       sin3-associated polypeptide, 18 kDa
                      208740_at      SAP18       sin3-associated polypeptide, 18 kDa
                      208590_x\_at   GJA3        Gap junction protein, alpha 3, 46 kDa (connexin 46)
                      207302_at      SGCG        Sarcoglycan, gamma (35 kDa dystrophin-associated glycoprotein)
                      206404_at      FGF9        Fibroblast growth factor 9 (glia-activating factor)
                      204387_x\_at   MRP63       Mitochondrial ribosomal protein 63
                      204386_s\_at   MRP63       Mitochondrial ribosomal protein 63
                      204305_at      MIPEP       Mitochondrial intermediate peptidase

[^1]: Academic Editor: Ilana Zalcberg Renault
